I. Definition & Pathophysiology

Peptic ulcer disease (PUD) is characterized by localized defects in the gastroduodenal mucosa that extend through the muscularis mucosae, resulting from an imbalance between aggressive factors (e.g., gastric acid, pepsin, Helicobacter pylori virulence factors) and defensive mechanisms (e.g., mucus-bicarbonate barrier, mucosal blood flow, epithelial restitution, prostaglandin synthesis).

Key pathophysiiological insights:

• Acid-peptic axis: Gastric acid remains central—even with successful H. pylori eradication or PPI therapy, baseline acid secretion may remain elevated in some patients due to hypergastrinemia (especially in duodenal ulcers).
• H. pylori pathogenesis:
  • cagA⁺/vacA s1/m1 strains confer higher risk of gastric atrophy, intestinal metaplasia, and adenocarcinoma.
  • H. pylori induces chronic inflammation (lymphoid follicles), disrupts tight junctions, reduces somatostatin (→ ↑ gastrin), and increases interleukin-1β and TNF-α (pro-inflammatory cytokines that inhibit acid secretion in the corpus but may exacerbate mucosal injury).
  • H. pylori impairs duodenal acid clearance via duodenogastric metaplasia, facilitating gastric acid exposure of the duodenal bulb.
• NSAID-induced ulcerogenesis:
  • COX-1 inhibition ↓ prostaglandin synthesis → reduced mucus/bicarbonate, mucosal blood flow, and epithelial repair.
  • Topical irritant effect on epithelium (“un ion-trapping” in acidic environment).
  • NSAIDs also inhibit COX-2 during ulcer healing; thus, chronic use delays healing.
• Other risk modifiers: Smoking (↓ mucosal blood flow, ↑ acid, ↓ bicarbonate), stress (e.g., critical illness → stress ulceration via splanchnic hypoperfusion), hypochlorhydria from long-term PPI use may promote C. difficile or small intestinal bacterial overgrowth—but does not directly cause PUD.

II. Clinical Presentation & Red Flags

Typical Symptoms

• Duodenal ulcers (DU): Episodic, burning epigastric pain 2–3 hours postprandial, often awakening patient at night; relieved by food or antacids.
• Gastric ulcers (GU): Pain 1–2 hours postprandial, not reliably relieved by food (may worsen with eating); more likely to present with nausea, early satiety.

Alarm Symptoms (Indicative of Malignancy or Complications)

(Per AGA 2021 Guidelines, ACG 2021 PUD Guidelines):

• Unintentional weight loss (>5% in <6 months)
• Persistent vomiting (suggesting outlet obstruction)
• Dysphagia/odynophagia (suggesting stricture or malignancy)
• Gastrointestinal bleeding: melena, hematemesis, or occult blood
• Iron deficiency anemia (IDA) unexplained by other causes—especially in men/postmenopausal women (strong predictor of upper GI malignancy; OR 3.4 for gastric cancer; Clin Gastroenterol Hepatol 2020)
• Age ≥50–60 years with new-onset dyspepsia (risk of gastric cancer rises steeply after age 55; Gut 2017)
• Palpable abdominal mass or cervical/epigastric lymphadenopathy
• Family history of upper GI malignancy in first-degree relatives (esp. gastric cancer; OR ~2.0)

Note: Age cutoff varies—some guidelines (e.g., NICE UK 2024) recommend endoscopy for age ≥55 with new dyspepsia; others use 60. The threshold should be individualized in high-prevalence regions.

III. Diagnostic Workup: Algorithmic Approach

A. When to Perform Endoscopy (AGA/ACG Recommendations)

Endoscopy is indicated if any of the following are present:

B. Role of Noninvasive Testing: H. pylori

1. Test-and-treat strategy is appropriate for patients <60 years without alarm features, especially in low-malignancy-risk regions (sensitivity 85–95% for active PUD).
2. Preferred tests:
   • Urea breath test (UBT): Sensitivity/specificity >95%; ideal for pre- and post-treatment evaluation. Must discontinue PPIs ≥14 days, antibiotics ≥4 weeks prior.
   • Stool antigen test (monoclonal): Sensitivity 94%, specificity 96% (Ann Intern Med 2020); unaffected by PPIs (but performance ↓ if GI bleeding or recent PPI/antibiotic use).
3. Serology: Not recommended in active PUD—it detects past exposure, not current infection; useful only for epidemiologic screening or when other tests unavailable.

Biopsy Recommendations (ACG 2021; WGO Global Guidelines 2024):

• Gastric ulcers: Mandatory biopsies from both ulcer edge and adjacent non-ulcerated mucosa (至少 4–6 samples) to exclude malignancy.
  • Gastric adenocarcinoma occurs in ~5–10% of endoscopically diagnosed “ulcers” initially thought benign (Gastroenterology 2022).
  • Biopsy for H. pylori, histology (for atrophy, intestinal metaplasia), and rapid urease test.
• Duodenal ulcers: No routine biopsy needed unless atypical appearance (e.g., irregular margins, friability, bleeding)—malignancy is exceptionally rare (<0.5%).

IV. Management: Evidence-Based Strategies

A. H. pylori-Associated PUD

Eradication is first-line therapy and leads to ulcer healing in >90% of cases—superior to acid suppression alone (Cochrane 2023 meta-analysis: pooled OR 5.7 for sustained ulcer remission).

Recommended Regimens (ACG 2021, Maastricht VI/Florence Consensus 2022):

Post-treatment testing:

• Confirm eradication with UBT or fecal antigen ≥4 weeks after therapy (after PPI cessation).
• Retest all patients with PUD—not optional—even if asymptomatic.

B. NSAID-Induced PUD

NSAID alternatives:

• Acetaminophen (first-line for mild-moderate pain)
• Topical NSAIDs (e.g., diclofenac gel—low systemic absorption)
• COX-2 inhibitors only with PPI co-therapy in high GI risk patients

C. Idiopathic PUD

• Treated with PPI for 6–8 weeks; healing rates ~85–90% (Am J Gastroenterol 2020).
• Consider maintenance therapy (e.g., omeprazole 10 mg OD) in:
  • Recurrent ulcers
  • High-risk comorbidities (e.g., anticoagulant use, renal failure)
  • Persistent symptoms despite healing

D. Acute Upper GI Bleeding from PUD

• Clinical assessment: Blatchford score or Rockall score to triage risk (score ≥2 suggests need for hospitalization/endoscopy).
• Urgent endoscopy (<24 hours) for hemodynamic instability, melena + Hb drop >3 g/dL, or age >65.
• High-dose PPI protocol post-endoscopy:
  • Bolus: IV pantoprazole 80 mg
  • Infusion: 8 mg/h for 72 hours (for high-risk stigmata—Forrest I–IIa)
  • Oral PPIs are inferior in acute bleed management (Lancet 2010; SCURRI trial).

Endoscopic therapy:

• Injection epinephrine + thermal coagulation/hemoclips for active bleeding or visible vessel (Forrest I–IIa)
• Adrenaline + fibrin glue for adherent clot (Forrest IIb)

E. Surgical Indications

• Perforation (>12 hours = high mortality; requires laparoscopic washout + omental patch)
• Penetration into adjacent organ (e.g., pancreas—may require drainage + PPI long-term)
• Obstruction (persistent vomiting, dilated stomach on NG tube)—may need gastroduodenoplasty
• Uncontrolled bleeding after 2–3 endoscopic interventions

V. Adjunctive & Supportive Measures

Dietary Considerations

• Avoid symptom triggers: Citric acid (e.g., lemon juice), caffeine, alcohol, and smoked/fried foods may ↓ lower esophageal sphincter pressure or directly irritate mucosa—but no strong evidence they impair ulcer healing (Eur J Gastroenterol Hepatol 2022).
• Pro-healing nutrients (limited evidence, but low-risk):
  • Protein: Supports epithelial repair
  • Zinc: Cofactor for mucosal regeneration (trials show faster healing with zinc supplementation in H. pylori-negative ulcers; Dig Dis Sci 2019)
  • Vitamin B12/folate: Critical in atrophic gastritis or post-gastrectomy
  • Probiotics (e.g., Lactobacillus spp., S. boulardii) may improve eradication rates and reduce antibiotic side effects (meta-analysis, Front Cell Infect Microbiol 2023)

PPI Safety & tapering

• Long-term PPI use associated with:
  • Vitamin B12 deficiency (↓ acid-dependent intrinsic factor release)
  • Hypomagnesemia (TRPM6 channel inhibition)
  • C. difficile infection (OR 1.74; JAMA Intern Med 2016)
• Tapering strategy: Reduce to H2RA or on-demand PPI after healing in non-high-risk patients.

VI. Key Clinical Pearls for Physicians

1. Age cutoff matters: In U.S./Europe, age ≥50–60 warrants endoscopy for new-onset dyspepsia; in Asia (high gastric cancer incidence), consider <45 years.
2. Iron-deficiency anemia = red flag: Even without overt bleeding—screen with EGD + colonoscopy if indicated.
3. NSAID ulcer risk stratification:
   • High: >60 y/o, history of ulcer, concomitant anticoagulant/steroid, high NSAID dose
   • Low: <60 y/o, no comorbidities, intermittent use
4. “Test-and-treat” is safe only in low-prevalence regions (e.g., North America/Europe) with negative H. pylori serology—avoid in high-prevalence areas (Asia, Latin America) due to false negatives and cancer risk.

Summary of guideline-based recommendations

References:

1. Chey WD, et al. ACG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2021.
2. Malfertheiner P, et al. Maastricht VI/Florence Consensus Report. Gut 2022.
3. Laine L, et al. NSAID-Induced GI Damage: Prevention & Management. Clin Gastroenterol Hepatol 2019.
4. Ford AC, et al. Efficacy of Helicobacter pylori Eradication in Preventing Peptic Ulcer Recurrence. Cochrane Database Syst Rev 2023.

This refined summary integrates current evidence, risk stratification nuance, and practical decision tools to support clinical reasoning—critical for optimizing outcomes in patients with peptic ulcer disease.